Skip to content

Management of oral lichen planus with triamcinolone acetonide and injectable platelet-rich fibrin

Management of oral lichen planus lesions using intralesional platelet-rich fibrin and triamcinolone acetonide injection

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN11783938
Enrollment
12
Registered
2021-07-09
Start date
2019-09-15
Completion date
Unknown
Last updated
2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bilateral oral lichen planus lesions Skin and Connective Tissue Diseases Lichen planus

Interventions

This study is a split-mouth randomised clinical trial. Participants are randomised by coin toss to decide which side of their mouth is to be treated by injectable platelet-rich fibrin and which is to

Sponsors

Damascus University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed with oral lichen planus lesions

Exclusion criteria

Exclusion criteria: 1. Patients with systemic disease 2. A history of topical therapy for oral lichen planus in the last 2 weeks or systemic treatment for oral lichen planus in the last 3 months 3. Pregnancy or lactation 4. Patients who had taken immunodepressant drugs the past 3 months

Design outcomes

Primary

MeasureTime frame
Pain measured using a Visual Analog Scale (VAS) once a week during treatment for 4 weeks

Secondary

MeasureTime frame
1. Clinical presentation of oral lichen planus measured using the REU scoring system at 1, 2, 3 and 4 weeks 2. Treatment response: surface areas of erythema and ulceration measured with a sterile flexible periodontal scale probe at 1, 2, 3 and 4 weeks 3. Recurrence rate measured by clinical examination at the end of treatment (day 30) 4. Quality of life measured using OHIP- 14 before treatment and at the end of treatment (day 30)

Countries

Syria

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026